Achillion Pharmaceuticals reports that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients with paroxysmal nocturnal hemoglobinuria (PNH) who are sub-optimal responders to a C5 inhibitor alone.
“The FDA designation underscores the urgent need for new treatment options for patients living with PNH,” said Joe Truitt, President and Chief Executive Officer at Achillion. more